Identification of miR‑125a‑5p as a tumor suppressor of renal cell carcinoma, regulating cellular proliferation, migration and apoptosis

Chen,Duqun; Li,Yifan; Su,Zhengming; Yu,Zuhu; Yu,Wenshui; Li,Yuchi; Gui,Yaoting; Yang,Shangqi; Lai,Yongqing

doi:10.3892/mmr.2014.2848

Identification of miR‑125a‑5p as a tumor suppressor of renal cell carcinoma, regulating cellular proliferation, migration and apoptosis

Authors:
- Duqun Chen
- Yifan Li
- Zhengming Su
- Zuhu Yu
- Wenshui Yu
- Yuchi Li
- Yaoting Gui
- Shangqi Yang
- Yongqing Lai
View Affiliations

Affiliations: Department of Urology, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU‑HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China, The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU‑HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
Published online on: November 3, 2014 https://doi.org/10.3892/mmr.2014.2848
Pages: 1278-1283

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

miR‑125a‑5p has been previously described as a tumor suppressor in numerous malignancies, however the expression and function of miR‑125a‑5p in renal cell carcinoma (RCC) remains to be elucidated. In the present study, to explore the potential role of miR‑125a‑5p in RCC, quantitative polymerase chain reaction was used to determine the expression levels of miR‑125a‑5p in renal cancer tissues. The influence of miR‑125a‑5p on cell proliferation, migration and apoptosis was also determined, using an MTT assay, a wound scratch assay and flow cytometry, respectively. The expression of miR‑125a‑5p was shown to be decreased in RCC and the restoration of miR‑125a‑5p by synthetic mimics was shown to suppress cell proliferation and migration, and induce apoptosis. The present results indicate that miR‑125a‑5p may function as a tumor suppressor in RCC. The present study is, to the best of our knowledge, the first to demonstrate the downregulation of miR‑125a‑5p in RCC, and to show the role it has in affecting cellular proliferation, migration and apoptosis. Further research is needed to define the target genes of miR‑125a‑5p and explore the potential of miR‑125a‑5p as a diagnostic or a prognostic biomarker for RCC.

View Figures

View References

1	Cairns P: Renal cell carcinoma. Cancer Biomark. 9:461–473. 2010.
2	McLaughlin JK, Lipworth L and Tarone RE: Epidemiologic aspects of renal cell carcinoma. Semin Oncol. 33:527–533. 2006. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
4	Chow WH and Devesa SS: Contemporary epidemiology of renal cell cancer. Cancer J. 14:288–301. 2008. View Article : Google Scholar : PubMed/NCBI
5	Rasmussen F: Metastatic renal cell cancer. Cancer Imaging. 13:374–380. 2013. View Article : Google Scholar : PubMed/NCBI
6	Wu L and Belasco JG: Micro-RNA regulation of the mammalian lin-28 gene during neuronal differentiation of embryonal carcinoma cells. Mol Cell Biol. 25:9198–9208. 2005. View Article : Google Scholar : PubMed/NCBI
7	Vaz C, Ahmad HM, Sharma P, et al: Analysis of microRNA transcriptome by deep sequencing of small RNA libraries of peripheral blood. BMC Genomics. 11:2882010. View Article : Google Scholar : PubMed/NCBI
8	Lin Y, Zeng Y, Zhang F, et al: Characterization of microRNA expression profiles and the discovery of novel microRNAs involved in cancer during human embryonic development. PLoS One. 8:e692302013. View Article : Google Scholar : PubMed/NCBI
9	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar :
10	Wang S, Huang J, Lyu H, et al: Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced dowregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis. 4:e5562013. View Article : Google Scholar
11	Li W, Duan R, Kooy F, et al: Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet. 46:358–360. 2009. View Article : Google Scholar : PubMed/NCBI
12	Lee CH, Kuo WH, Lin CC, et al: MicroRNA-regulated protein-protein interaction networks and their functions in breast cancer. Int J Mol Sci. 14:11560–11606. 2013. View Article : Google Scholar : PubMed/NCBI
13	Bi Q, Tang S, Xia L, et al: Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 7:e401692012. View Article : Google Scholar : PubMed/NCBI
14	Karsy M, Arslan E and Moy F: Current progress on understanding microRNAs in glioblastoma multiforme. Genes Cancer. 3:3–15. 2012. View Article : Google Scholar : PubMed/NCBI
15	Osanto S, Qin Y, Buermans HP, et al: Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One. 7:e382982012. View Article : Google Scholar : PubMed/NCBI
16	Jing Q, Huang S, Guth S, et al: Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell. 120:623–634. 2005. View Article : Google Scholar : PubMed/NCBI
17	Guo S, Bai H, Megyola CM, et al: Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms. Proc Natl Acad Sci USA. 109:16636–16641. 2012. View Article : Google Scholar : PubMed/NCBI
18	Zaman MS, Shahryari V, Deng G, et al: Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One. 7:e310602012. View Article : Google Scholar : PubMed/NCBI
19	Zhao A, Li G, Péoc’h M, Genin C and Gigante M: Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 94:115–120. 2013. View Article : Google Scholar
20	Slaby O, Redova M, Poprach A, et al: Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer. 51:707–716. 2012. View Article : Google Scholar : PubMed/NCBI
21	Redova M, Poprach A, Nekvindova J, et al: Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 10:552012. View Article : Google Scholar : PubMed/NCBI
22	Khella HW, Bakhet M, Allo G, et al: miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis. 34:2231–2239. 2013. View Article : Google Scholar : PubMed/NCBI
23	Murata K, Furu M, Yoshitomi H, et al: Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. PLoS One. 8:e691182013. View Article : Google Scholar : PubMed/NCBI
24	Coppola N, Potenza N, Pisaturo M, et al: Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One. 8:e653362013. View Article : Google Scholar : PubMed/NCBI
25	Nishida N, Mimori K, Fabbri M, et al: MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res. 17:2725–2733. 2011. View Article : Google Scholar : PubMed/NCBI
26	Hashiguchi Y, Nishida N, Mimori K, et al: Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int J Oncol. 40:1477–1482. 2012.PubMed/NCBI
27	Pazo Cid RA and Antón A: Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol. 85:350–362. 2013. View Article : Google Scholar
28	Smith MB, Reardon J and Olson EM: Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer. Drugs Today (Barc). 48:713–722. 2012.
29	Sendur MA, Aksoy S and Altundag K: Pertuzumab in HER2-positive breast cancer. Curr Med Res Opin. 28:1709–1716. 2012. View Article : Google Scholar : PubMed/NCBI